Rafn, Bolette Skjødt
Andersen, Martin Færch
Sørensen, Victor
Bjerre, Eik Dybboe
Baandrup, Lone
Vernal, Ditte Lammers
Mors, Ole
Knop, Filip Krag
Wolf, Rasmus Trap
Tolver, Anders
Firth, Joseph
Nøhr, Nikolaj
Skou, Søren T.
Ebdrup, Bjørn H.
Midtgaard, Julie
Funding for this research was provided by:
TrygFonden (151603, 151603, 151603, 151603)
Royal Library, Copenhagen University Library
Article History
Received: 16 March 2023
Accepted: 7 August 2023
First Online: 30 August 2023
Declarations
:
: The trial was approved by the Ethics Committee for the Capital Region of Denmark (H-21079211) All participants will provide written informed consent prior to enrolment. The study is being conducted in compliance with the principles of the Declaration of Helsinki.
: Not applicable.
: BHE has received lecture fees and/or is part of Advisory Boards of Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Otsuka Pharma Scandinavia AB, Takeda Pharmaceutical Company, Boehringer Ingelheim, and Lundbeck Pharma A/S. EDB is employed as clinical project lead at Novo Nordisk. DLV has received speaking fees from Lundbeck Pharma A/S and is the sub-investigator at the Aalborg site of the Boehringer Ingelheim Connex trial. RTW is employed as senior health economist at Bristol Myers Squibb. FKK has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara; and is a minority shareholder in Antag Therapeutics and co-owner of the weight loss clinic <i>Medicinsk Vægttabsbehandling ApS</i>. NN is employed at the commercial functional gym that hosts the Vega Exercise Community (Arca). All other authors declare that they have no competing interests.